Leveraging Health Information Technology and Team Change to Improve Cardiovascular Disease Prevention in Rheumatoid Arthritis, The TEACH RA Study

CO-PRINCIPAL INVESTIGATORS: DARCY MAJKA MD, MS, STEPHEN PERSELL, MD, MPH
FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL

Multifaceted intervention to address CVD risk in Rheumatoid Arthritis

- ▶ Background: CVD risk is increased in RA; risk factors are under addressed

- ▶ Objectives: to implement and test the impact of system-level quality improvement strategies on the assessment, recognition and management of CVD risk factors in rheumatoid arthritis patients

- ▶ Setting: large academic rheumatology practice and referring primary care practices

- ▶ Participants: adults with RA

- ▶ Methods: Measure electronic clinical quality measures (eCQMs) related to CVD prevention using EHR data

- ▶ Analysis using interrupted time series analysis of repeated eCQMs

Intervention Components

- Intervention Phase 1
  - Clinician education
  - Point-of-care electronic clinical decision support
  - Performance feedback to clinicians
  - Care management directed at patients (encouraging risk factor testing and addressing CVD risk within rheumatology practice)
- Intervention Phase 2
  - Care management directed at patients and primary care physicians (encouraging risk factor treatment in primary care)

Changes in CVD Prevention Measures in RA Patients Over Time-Initial Intervention, Phase 1

Risk factor assessment increased significantly in Phase 1

Pre-intervention | Implementation | Early Maintenance | Late Maintenance

Legend:
- % of pts with major CVD risk fators assessed
- # ot Statin Treatment for High Risk population
- % of Statin Treatment for the RA cohort
- % of diagnosis documentation for Hypertensive patients
- % of Controlled Hypertension
- % of non-smoking among ever smokers
- % of Antithombotic treatment in IVD

Changes in Statin Prescribing for Primary Prevention in RA Patients Over Time, Phase 2

Care management directed at patients and PCPs significantly increased statin prescribing for primary CVD prevention in RA